[go: up one dir, main page]

BR9815340A - Utilização de pelo menos um ativador dos receptores de tipo ppar-y. - Google Patents

Utilização de pelo menos um ativador dos receptores de tipo ppar-y.

Info

Publication number
BR9815340A
BR9815340A BR9815340-4A BR9815340A BR9815340A BR 9815340 A BR9815340 A BR 9815340A BR 9815340 A BR9815340 A BR 9815340A BR 9815340 A BR9815340 A BR 9815340A
Authority
BR
Brazil
Prior art keywords
ppar
activator
type receivers
type
receivers
Prior art date
Application number
BR9815340-4A
Other languages
English (en)
Inventor
Michel Rivier
Irina Safonova
Serge Michel
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of BR9815340A publication Critical patent/BR9815340A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

''UTILIZAçãO DE PELO MENOS UM ATIVADOR DOS RECEPTORES DE TIPO PPAR-<sym>'' A presente invenção refere-se a utilização de pelo menos um ativador dos receptores de tipo PPAR-<sym> na preparação de uma composição farmacêutica, composição essa destinada a tratar as desordens cutâneas ligadas a uma anomalia da diferenciação das células epidérmicas.
BR9815340-4A 1997-12-31 1998-12-28 Utilização de pelo menos um ativador dos receptores de tipo ppar-y. BR9815340A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9716808A FR2773075B1 (fr) 1997-12-31 1997-12-31 Utilisation d'activateurs de ppar-gamma en dermatologie
PCT/FR1998/002894 WO1999034783A1 (fr) 1997-12-31 1998-12-28 UTILISATION D'ACTIVATEURS DE PPAR-η EN DERMATOLOGIE

Publications (1)

Publication Number Publication Date
BR9815340A true BR9815340A (pt) 2000-10-31

Family

ID=9515385

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815340-4A BR9815340A (pt) 1997-12-31 1998-12-28 Utilização de pelo menos um ativador dos receptores de tipo ppar-y.

Country Status (13)

Country Link
US (1) US6403656B1 (pt)
EP (1) EP1041977B1 (pt)
JP (1) JP3773790B2 (pt)
AT (1) ATE402698T1 (pt)
AU (1) AU745187B2 (pt)
BR (1) BR9815340A (pt)
CA (1) CA2314607C (pt)
DE (1) DE69839815D1 (pt)
ES (1) ES2310019T3 (pt)
FR (1) FR2773075B1 (pt)
NO (1) NO325171B1 (pt)
NZ (1) NZ505089A (pt)
WO (1) WO1999034783A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
CA2416788A1 (en) * 2000-07-31 2002-02-07 Tamar Tennenbaum Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2002038150A1 (de) * 2000-11-09 2002-05-16 Phenion Gmbh & Co. Kg Aktivatoren von peroxisom-proliferator-aktivierten rezeptoren alpha, beta als arzneimittel zur behandlung von immunologisch bedingten hautstörungen
WO2002087576A1 (en) * 2001-04-30 2002-11-07 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
DE10204398A1 (de) * 2002-02-04 2003-08-14 Univ Goettingen Georg August Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US20040115637A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of PPAR-alpha expression
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
AU2004263009B2 (en) * 2003-08-07 2009-12-24 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2007513173A (ja) * 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ZA200802546B (en) * 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
KR100702415B1 (ko) * 2006-03-03 2007-04-09 안웅식 올리고 핵산 탐침 비드 어레이를 이용한 인유두종바이러스검출 키트 및 방법
EP2185184A2 (en) * 2007-07-30 2010-05-19 HealOr Ltd. Pharmaceutical composition for treating wounds and related methods
US20090291986A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas Composition and method of treating facial skin defect
US20090291066A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas composition and method of treating facial skin defect
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
SI2805746T1 (sl) 2009-02-16 2020-10-30 Nogra Pharma Limited Alkilamido spojine in njihova uporaba
WO2010097788A2 (en) * 2009-02-24 2010-09-02 Healor Ltd. Visfatin therapeutic agents for the treatment of acne and other conditions
AR073505A1 (es) * 2009-09-10 2010-11-10 Monte Verde S A Composiciones y metodos para el tratamiento de enfermedades proliferativas
CA2789972A1 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
US20110274775A1 (en) * 2010-05-07 2011-11-10 Michael Anthonavage Extracts of southernwood and topical uses thereof
US20110274776A1 (en) * 2010-05-07 2011-11-10 Michael Anthonavage Compositions comprising extracts of southernwood and an amine compound
ES2397889B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
EP2811993B1 (en) 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
MX2014012652A (es) 2012-04-18 2014-11-25 Nogra Pharma Ltd Metodo de tratamiento de la intolerancia a la lactosa.
FR3049864A1 (fr) 2016-04-06 2017-10-13 Naturex Extrait vegetal issu d'une plante du genre aerva, composition le contenant et utilisation dudit extrait vegetal
PT3921299T (pt) 2019-02-08 2025-02-17 Nogra Pharma Ltd Processo de fabrico do ácido 3-(4'-aminofenil)-2- metoxipropiónico, bem como dos seus análogos e intermediários
IT202000027489A1 (it) * 2020-11-17 2022-05-17 Mauro Michele Maria Picardo Attivatori selettivi dei recettori attivati da proliferatori peroxisomiali (PPARs) per il trattamento della vitiligine
CN116548385B (zh) * 2023-04-20 2023-10-27 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 自发型系统性红斑狼疮动物模型的构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014824A1 (en) * 1988-01-14 1990-12-13 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of eczema
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5443844A (en) * 1992-12-03 1995-08-22 Mcdaniel; William R. Linoleic acid preparations for topical treatment of acne vulgaris
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
AU4233297A (en) * 1996-08-23 1998-03-06 Arch Development Corporation Identification of activators and inhibitors of sebum formation
ATE462433T1 (de) * 1996-12-11 2010-04-15 Dana Farber Cancer Inst Inc Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
EP1019059A4 (en) * 1997-01-24 2004-01-14 Univ California USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Also Published As

Publication number Publication date
FR2773075B1 (fr) 2000-05-05
EP1041977B1 (fr) 2008-07-30
NO20003414D0 (no) 2000-06-29
EP1041977A1 (fr) 2000-10-11
US6403656B1 (en) 2002-06-11
AU745187B2 (en) 2002-03-14
DE69839815D1 (de) 2008-09-11
FR2773075A1 (fr) 1999-07-02
JP2002500179A (ja) 2002-01-08
NO20003414L (no) 2000-08-31
WO1999034783A1 (fr) 1999-07-15
CA2314607C (fr) 2009-02-03
JP3773790B2 (ja) 2006-05-10
NZ505089A (en) 2002-12-20
CA2314607A1 (fr) 1999-07-15
AU2057599A (en) 1999-07-26
ATE402698T1 (de) 2008-08-15
ES2310019T3 (es) 2008-12-16
NO325171B1 (no) 2008-02-11

Similar Documents

Publication Publication Date Title
BR9815340A (pt) Utilização de pelo menos um ativador dos receptores de tipo ppar-y.
PT813525E (pt) Derivados de benzamidina e sua utilizacao como anticoagulantes
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
DE69939864D1 (de) Ppar-gamma modulatoren
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
NO20003600D0 (no) Kaliumkanal inhibitorer
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE250571T1 (de) Kaliumkanal-blocker
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
PT934310E (pt) N-heterociclicos monociclicos substituidos por tioacido uteis como anti-coagulantes
EA200001176A1 (ru) Гетероциклические ингибиторы p38
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000098A1 (ru) 4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
BR9811099A (pt) Inibidores de urocinase
ES2188979T3 (es) Derivados de benzamidina sustituidos con derivados de aminoacidos ciclicos e hidroxiacidos ciclicos, y su uso como anti-coagulantes.
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
PT888271E (pt) Derivados de benzamidina substituidos com derivados de aminoacidos e hidroxiacidos e sua utilizacao como anticoagulantes
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
ES529593A0 (es) Procedimiento para preparar nuevos derivados de benzazocinona y de benzazoninona
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM ART. 13 DA LPI ); NAO APRESENTA SUFICIENCIA DESCRITIVA ( ART. 24 DA LPI )

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.